Cargando…

Desensitization Protocol to Carboplatin: A Technical Report

Carboplatin is one of the most widely used chemotherapy agents for solid tumors. One of the most common major side effects is the hypersensitivity reaction, and the likelihood of it increases with the number of courses given. Permanent discontinuation of carboplatin is not required if this side effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nitipir, Cornelia, Parosanu, Andreea, Popa, Ana Maria, Cotan, Horia, Olaru, Mihaela, Iaciu, Cristian, Orlov Slavu, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136189/ https://www.ncbi.nlm.nih.gov/pubmed/35651423 http://dx.doi.org/10.7759/cureus.24515

Ejemplares similares

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
por: Pirlog, Cristina-Florina, et al.
Publicado: (2022)

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy
por: Parosanu, Andreea, et al.
Publicado: (2022)

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature
por: Pîrlog, Cristina-Florina, et al.
Publicado: (2022)

Restricted Mean Survival Time—Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?
por: Pîrlog, Cristina-Florina, et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study
por: Nitipir, Cornelia, et al.
Publicado: (2022)

Use of Immune Checkpoint Inhibitors in Elderly Patients With Chronic Kidney Disease and Renal Cell Carcinoma Metastasis of the Parotid Gland: Case Report and Review of the Literature
por: Parosanu, Andreea, et al.
Publicado: (2022)

Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study
por: Nitipir, Cornelia, et al.
Publicado: (2021)

The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer
por: Orlov-Slavu, Maria Cristina, et al.
Publicado: (2021)

Local recurrence management of extremity soft tissue sarcoma
por: Serban, Bogdan, et al.
Publicado: (2023)

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023)

Possible Influence of Weight Gain and Creatinine Levels in Predicting Response to Nivolumab: A Multicenter Analysis
por: Nitipir, Cornelia, et al.
Publicado: (2020)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

A desensitization protocol to ganciclovir
por: Cernadas, Josefina Rodrigues, et al.
Publicado: (2014)

Interdisciplinary Healthcare Team Experience of Carboplatin and Oxaliplatin Desensitizations in a Tertiary Referral University Hospital
por: Tunakan Dalgic, Ceyda, et al.
Publicado: (2023)

Management of Lung Cancer Presenting with Solitary Bone Metastasis
por: Nistor, Claudiu-Eduard, et al.
Publicado: (2022)

4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study
por: Nishimura, Meiko, et al.
Publicado: (2021)

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases
por: Radu, Letitia-Elena, et al.
Publicado: (2020)

Improvement of Breast Cancer-Associated Pulmonary Tumor Thrombotic Microangiopathy With Carboplatin and Gemcitabine
por: Tran, Helen, et al.
Publicado: (2023)

Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study
por: Paksoy, Nail, et al.
Publicado: (2022)

394 Desensitization Protocol to Methotrexate
por: Maya, Jonathan, et al.
Publicado: (2012)

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis
por: Qiu, Weitao, et al.
Publicado: (2022)

Active Role of the Necrotic Zone in Desensitization of Hypoxic Macrophages and Regulation of CSC-Fate: A hypothesis
por: Mehrabi, Maryam, et al.
Publicado: (2018)

Modified oral metronidazole desensitization protocol
por: Gendelman, Samantha R., et al.
Publicado: (2014)

Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries
por: Malhotra, Binu, et al.
Publicado: (2015)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
por: Langer, Corey J., et al.
Publicado: (2021)

Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer
por: Yang, Feng, et al.
Publicado: (2021)

Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer
por: Abreu de Oliveira, Willy Antoni, et al.
Publicado: (2021)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Does Carboplatin Rapid Desensitization Change Its Adverse Drug Reactions Other than Hypersensitivity and Efficacy in Patients With Ovarian Cancer?
por: Park, Han-Ki, et al.
Publicado: (2020)

Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient’s Stratification
por: Ginghina, Octav, et al.
Publicado: (2022)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
por: Takeshita, Naohiro, et al.
Publicado: (2022)

Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
por: Saigal, Kunal, et al.
Publicado: (2014)

Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
por: Kunos, Charles A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4uu7lse2ju1ejuc2mpgeage5f7